📣 VC round data is live. Check it out!

Sanara MedTech Valuation Multiples

Discover Sanara MedTech's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Lucid Diagnostics, Anika Therapeutics, Medinice, Asterasys and more.

Sanara MedTech Overview

About Sanara MedTech

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.


Founded

2001

HQ

United States

Employees

141

Financials (LTM)

Revenue: $109M
EBITDA: $17M

EV

$231M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sanara MedTech Financials

Sanara MedTech reported last 12-month revenue of $109M and EBITDA of $17M.

In the same LTM period, Sanara MedTech generated $101M in gross profit, $17M in EBITDA, and had net loss of ($21M).

Revenue (LTM)


Sanara MedTech P&L

In the most recent fiscal year, Sanara MedTech reported revenue of $103M and EBITDA of $17M.

Sanara MedTech is unprofitable as of last fiscal year, with gross margin of 93%, EBITDA margin of 16%, and net margin of (36%).

See analyst estimates for Sanara MedTech
LTMLast FY202320242025202620272028
Revenue$109M$103M$65M$87M$103M
Gross Profit$101M$96M$57M$79M$96M
Gross Margin92%93%88%91%93%
EBITDA$17M$17M($289K)($2M)$10M
EBITDA Margin15%16%(0%)(2%)10%
EBIT Margin8%9%(12%)(10%)9%
Net Profit($21M)($38M)($4M)($10M)($38M)
Net Margin(19%)(36%)(7%)(11%)(36%)
Net Debt-$29M---

Financial data powered by Morningstar, Inc.

Sanara MedTech Stock Performance

Sanara MedTech has current market cap of $196M, and enterprise value of $231M.

Market Cap Evolution


Sanara MedTech's stock price is $21.36.

Sanara MedTech share price decreased by 6.3% in the last 30 days, and by 24.6% in the last year.

Sanara MedTech has an EPS (earnings per share) of $-4.10.

See more trading valuation data for Sanara MedTech
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$231M$196M-2.6%-6.3%24.3%-24.6%$-4.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sanara MedTech Valuation Multiples

Sanara MedTech trades at 2.1x EV/Revenue multiple, and 13.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Sanara MedTech

EV / Revenue (LTM)


Sanara MedTech Financial Valuation Multiples

As of June 3, 2026, Sanara MedTech has market cap of $196M and EV of $231M.

Sanara MedTech has a P/E ratio of (9.3x).

LTMLast FY202320242025202620272028
EV/Revenue2.1x2.2x3.5x2.7x2.2x
EV/EBITDA13.7x13.6xn/m(123.9x)22.4x
EV/EBIT27.5x25.2x(30.1x)(26.6x)25.2x
EV/Gross Profit2.3x2.4x4.0x2.9x2.4x
P/E(9.3x)(5.2x)(45.5x)(20.3x)(5.2x)
EV/FCF-107.8x(65.7x)n/m107.8x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sanara MedTech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sanara MedTech Margins & Growth Rates

Sanara MedTech grew revenue by 14% but EBITDA decreased by 2% in the last fiscal year.

In the most recent fiscal year, Sanara MedTech reported gross margin of 93%, EBITDA margin of 16%, and net margin of (36%).

See estimated margins and future growth rates for Sanara MedTech

Sanara MedTech Margins

Last FY202420252026202720282029
Gross Margin93%91%93%92%
EBITDA Margin16%(2%)10%14%
EBIT Margin9%(10%)9%8%
Net Margin(36%)(11%)(36%)1%
FCF Margin2%(0%)2%-

Sanara MedTech Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth14%33%19%14%
Gross Profit Growth13%37%22%13%
EBITDA Growth(2%)543%(654%)62%
EBIT Growth8%13%(206%)8%
Net Profit Growth(104%)125%289%(104%)
FCF Growth-(93%)(945%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Sanara MedTech Operational KPIs

Sanara MedTech's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.6M for the same period.

Sanara MedTech's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sanara MedTech's Rule of X is 50% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sanara MedTech
LTMLast FY202320242025202620272028
Rule of 4029%28%---
Bessemer Rule of X49%50%---
Revenue per Employee-$0.7M---
Opex per Employee-$0.6M---
R&D Expenses to Revenue5%5%6%7%5%
Opex to Revenue-84%100%101%84%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sanara MedTech Competitors

Sanara MedTech competitors include Lucid Diagnostics, Anika Therapeutics, Medinice, Asterasys, Ilex Medical, RxSight, TriSalus Life Sciences, Surgical Science, Deltex Medical Group and InfuSystem.

Most Sanara MedTech public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Lucid Diagnostics44.1x35.6x(3.7x)(4.0x)
Anika Therapeutics1.6x1.5x33.0x24.0x
Medinice--(111.9x)-
Asterasys7.5x6.3x22.7x18.2x
Ilex Medical0.4x-3.3x-
RxSight(0.0x)(0.0x)0.1x0.0x
TriSalus Life Sciences4.0x3.7x(11.1x)(12.2x)
Surgical Science1.0x1.0x5.6x6.1x

This data is available for Pro users. Sign up to see all Sanara MedTech competitors and their valuation data.

Start Free Trial

Acquisitions by Sanara MedTech

Sanara MedTech has acquired 2 companies to date.

Last acquisition by Sanara MedTech was on July 1st 2022. Sanara MedTech acquired Scendia Biologics for $7M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Sanara MedTech

Scendia Biologics
Precision Healing
Description
Scendia Biologics supplies orthobiologics and soft tissue repair products for various surgical procedures.
Precision Healing is a medical technology company providing wound healing assessment tools. San Francisco-headquartered, it deploys AI-powered imaging platforms to evaluate wound state and predict healing trajectories for clinicians. The system analyzes tissue composition, infection risk, and perfusion data from standard smartphone cameras, supporting chronic wound management in hospitals and outpatient clinics across the United States.
HQ CountryUnited StatesUnited States
HQ City
Orlando, FL
Boston, MA
Deal Date1 Jul 20224 Apr 2022
Valuation$7M$8M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sanara MedTech acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Sanara MedTech

Sanara MedTech has invested in 1 company to date.

Latest investment by Sanara MedTech was on January 21st 2025. Sanara MedTech invested in Biomimetic Innovations in their $4M Strategic investment round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Sanara MedTech

Biomimetic Innovations
Description
Biomimetic Innovations is a medical device company commercializing synthetic biomaterials for tissue repair. Through pbcbiomed.com, the firm advances regenerative technologies targeting orthopedic, dental, and wound healing applications with scaffold materials that promote natural healing processes.
HQ CountryIreland
HQ City
Shannon
Deal Date21 Jan 2025
RoundStrategic investment
Raised$4M
InvestorsSanara MedTech
Valuation$74M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sanara MedTech investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sanara MedTech

When was Sanara MedTech founded?Sanara MedTech was founded in 2001.
Where is Sanara MedTech headquartered?Sanara MedTech is headquartered in United States.
How many employees does Sanara MedTech have?As of today, Sanara MedTech has over 141 employees.
Who is the CEO of Sanara MedTech?Sanara MedTech's CEO is Seth D. Yon.
Is Sanara MedTech publicly listed?Yes, Sanara MedTech is a public company listed on Nasdaq.
What is the stock symbol of Sanara MedTech?Sanara MedTech trades under SMTI ticker.
When did Sanara MedTech go public?Sanara MedTech went public in 2020.
Who are competitors of Sanara MedTech?Sanara MedTech main competitors include Lucid Diagnostics, Anika Therapeutics, Medinice, Asterasys, Ilex Medical, RxSight, TriSalus Life Sciences, Surgical Science, Deltex Medical Group, InfuSystem.
What is the current market cap of Sanara MedTech?Sanara MedTech's current market cap is $196M.
What is the current revenue of Sanara MedTech?Sanara MedTech's last 12 months revenue is $109M.
What is the current revenue growth of Sanara MedTech?Sanara MedTech revenue growth (NTM/LTM) is 13%.
What is the current EV/Revenue multiple of Sanara MedTech?Current revenue multiple of Sanara MedTech is 2.1x.
What is the current EBITDA of Sanara MedTech?Sanara MedTech's last 12 months EBITDA is $17M.
What is Sanara MedTech's EBITDA margin?Sanara MedTech's last 12 months EBITDA margin is 15%.
What is the current EV/EBITDA multiple of Sanara MedTech?Current EBITDA multiple of Sanara MedTech is 13.7x.
How many companies Sanara MedTech has acquired to date?As of June 2026, Sanara MedTech has acquired 2 companies.
What was the largest acquisition by Sanara MedTech?$8M acquisition of Precision Healing on 4th April 2022 was the largest M&A Sanara MedTech has done to date.
What companies Sanara MedTech acquired?Sanara MedTech acquired Precision Healing and Scendia Biologics.
In how many companies Sanara MedTech has invested to date?As of June 2026, Sanara MedTech has invested in 1 company.
What was the last Sanara MedTech investment?On 21st January 2025 Sanara MedTech invested in Biomimetic Innovations, participating in a $4M Strategic investment round at $74M valuation.
In what companies Sanara MedTech invested in?Sanara MedTech invested in Biomimetic Innovations.

See public comps similar to Sanara MedTech

Lists including Sanara MedTech

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial